CA2582385A1 - Formulations therapeutiques de traitement des affections rattachees a la proteine beta-amyloide - Google Patents
Formulations therapeutiques de traitement des affections rattachees a la proteine beta-amyloide Download PDFInfo
- Publication number
- CA2582385A1 CA2582385A1 CA002582385A CA2582385A CA2582385A1 CA 2582385 A1 CA2582385 A1 CA 2582385A1 CA 002582385 A CA002582385 A CA 002582385A CA 2582385 A CA2582385 A CA 2582385A CA 2582385 A1 CA2582385 A1 CA 2582385A1
- Authority
- CA
- Canada
- Prior art keywords
- agent
- foregoing
- amyloid
- pharmaceutical composition
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention a trait à des procédés et des compositions pharmaceutiques pour le traitement de maladies associées au bêta-amyloïde, y compris la maladie d'Alzheimer. L'invention a trait, par exemple, à un procédé de traitement thérapeutique concomitant d'un sujet, comprenant l'administration d'une quantité efficace d'un premier agent et d'un deuxième agent, ledit premier agent traitant une maladie associée au bêta-amyloïde, la dégénérescence, ou la toxicité cellulaire; et ledit deuxième agent étant un médicament thérapeutique ou un supplément nutritif.
Applications Claiming Priority (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87161304A | 2004-06-18 | 2004-06-18 | |
US10/871,365 | 2004-06-18 | ||
US10/871,514 US7414076B2 (en) | 2003-06-23 | 2004-06-18 | Methods and compositions for treating amyloid-related diseases |
US10/871,512 US20050038000A1 (en) | 2003-06-23 | 2004-06-18 | Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases |
US10/871,613 | 2004-06-18 | ||
US10/871,549 US20050142191A1 (en) | 2003-06-23 | 2004-06-18 | Pharmaceutical formulations of amyloid inhibiting compounds |
US10/871,543 | 2004-06-18 | ||
US10/871,512 | 2004-06-18 | ||
US10/871,537 | 2004-06-18 | ||
US10/871,537 US20050031651A1 (en) | 2002-12-24 | 2004-06-18 | Therapeutic formulations for the treatment of beta-amyloid related diseases |
US10/871,365 US7244764B2 (en) | 2003-06-23 | 2004-06-18 | Methods and compositions for treating amyloid-related diseases |
US10/871,543 US7253306B2 (en) | 2003-06-23 | 2004-06-18 | Pharmaceutical drug candidates and methods for preparation thereof |
US10/871,514 | 2004-06-18 | ||
US10/871,549 | 2004-06-18 | ||
PCT/IB2005/004199 WO2007049098A2 (fr) | 2004-06-18 | 2005-06-17 | Formulations therapeutiques pour le traitement de maladies associees au beta-amyloide |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2582385A1 true CA2582385A1 (fr) | 2005-12-18 |
Family
ID=37968188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002582385A Abandoned CA2582385A1 (fr) | 2004-06-18 | 2005-06-17 | Formulations therapeutiques de traitement des affections rattachees a la proteine beta-amyloide |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1841460A2 (fr) |
JP (1) | JP2008504372A (fr) |
CA (1) | CA2582385A1 (fr) |
WO (1) | WO2007049098A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010096925A1 (fr) * | 2009-02-26 | 2010-09-02 | Bellus Health (International) Limited | Matériau comestible complété et/ou enrichi en homotaurine, procédés de préparation et utilisations |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3851447T3 (da) | 2006-10-12 | 2023-12-04 | Bellus Health Inc | Fremgangsmåder, forbindelser, sammensætninger og vehikler til administration af 3-amino-1-propansulfonsyre |
EP2349233A4 (fr) * | 2008-10-09 | 2012-04-18 | Waratah Pharmaceuticals Inc | Utilisation de scyllo-inositols pour le traitement de troubles liés à la dégénérescence maculaire |
EP2349988A4 (fr) * | 2008-11-14 | 2012-05-02 | Bellus Health Inc | Sels nutritifs organiques, leurs procédés de préparation et leurs utilisations |
WO2011011060A1 (fr) | 2009-07-22 | 2011-01-27 | Puretech Ventures | Procédés et compositions de traitement de troubles, ceux-ci étant améliorés par l'activation du récepteur muscarinique |
US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
CA2777827C (fr) | 2009-10-30 | 2020-08-18 | Retrotope, Inc. | Soulagement de troubles lies au stress oxydatif par des derives de pufa |
KR102020611B1 (ko) | 2011-04-26 | 2019-09-10 | 레트로토프 인코포레이티드 | Pufa와 관련된 신경퇴행성 질환 및 근육 질환 |
AU2012249921B2 (en) | 2011-04-26 | 2017-06-08 | Biojiva Llc | Oxidative retinal diseases |
KR102020579B1 (ko) | 2011-04-26 | 2019-09-10 | 레트로토프 인코포레이티드 | 에너지 프로세싱 손상 장애 및 미토콘드리아 결함 |
WO2012148929A2 (fr) | 2011-04-26 | 2012-11-01 | Retrotope, Inc. | Troubles impliquant l'oxydation des acides gras polyinsaturés (pufa) |
RU2488388C1 (ru) * | 2012-05-24 | 2013-07-27 | Ооо "Валента Интеллект" | Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств |
CN102793694B (zh) * | 2012-08-14 | 2014-06-04 | 武汉华纳联合药业有限公司 | 3-氨基-1-丙烷磺酸及其衍生物在制备治疗脑卒中的药物中的应用 |
ES2871130T3 (es) | 2015-11-23 | 2021-10-28 | Retrotope Inc | Marcado isotópico específico del sitio de sistemas de 1, 4-dieno |
ITUA20161679A1 (it) * | 2016-03-15 | 2017-09-15 | Neuraxpharm Italy S P A | Composizione per prevenire e trattare patologie neurodegenerative e disturbi cognitivi |
KR102080023B1 (ko) | 2018-01-29 | 2020-02-21 | 주식회사 종근당 | 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물 |
KR102006777B1 (ko) | 2018-01-29 | 2019-10-08 | 주식회사 종근당 | 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제 |
JP7268049B2 (ja) | 2018-03-08 | 2023-05-02 | インサイト・コーポレイション | PI3K-γ阻害剤としてのアミノピラジンジオール化合物 |
US20210228519A1 (en) * | 2018-04-12 | 2021-07-29 | The Regents Of The University Of California | Methods for treating apoe4/4-associated disorders |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
CA3180743A1 (fr) | 2018-09-28 | 2020-04-02 | Karuna Therapeutics, Inc. | Composition comprenant de la xanomeline et du trospium pour le traitement de troubles ameliores par l'activation du recepteur muscarinique |
EP4107163A1 (fr) | 2020-02-21 | 2022-12-28 | Retrotope, Inc. | Procédés de modification isotopique d'acides gras polyinsaturés et leurs dérivés |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2395314A1 (fr) * | 1999-12-23 | 2001-11-15 | Neurochem, Inc. | Composes et methodes permettant la modulation de l'angiopathie cerebrale amyloide |
BR0317747A (pt) * | 2002-12-24 | 2005-11-22 | Neurochem Int Ltd | Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave |
-
2005
- 2005-06-17 WO PCT/IB2005/004199 patent/WO2007049098A2/fr active Application Filing
- 2005-06-17 CA CA002582385A patent/CA2582385A1/fr not_active Abandoned
- 2005-06-17 EP EP05858504A patent/EP1841460A2/fr not_active Withdrawn
- 2005-06-17 JP JP2007542367A patent/JP2008504372A/ja not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010096925A1 (fr) * | 2009-02-26 | 2010-09-02 | Bellus Health (International) Limited | Matériau comestible complété et/ou enrichi en homotaurine, procédés de préparation et utilisations |
Also Published As
Publication number | Publication date |
---|---|
EP1841460A2 (fr) | 2007-10-10 |
JP2008504372A (ja) | 2008-02-14 |
WO2007049098A3 (fr) | 2007-10-04 |
WO2007049098A2 (fr) | 2007-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003291910B2 (en) | Therapeutic formulations for the treatment of beta-amyloid related diseases | |
US20050031651A1 (en) | Therapeutic formulations for the treatment of beta-amyloid related diseases | |
CA2582385A1 (fr) | Formulations therapeutiques de traitement des affections rattachees a la proteine beta-amyloide | |
CN100571701C (zh) | 治疗β淀粉样蛋白相关疾病的治疗性制品 | |
JP4614460B2 (ja) | シトステロール血症の処置のための置換アゼチジノン化合物の使用 | |
US7244749B2 (en) | Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases | |
US6472400B1 (en) | Advanced gylcation end-product intermediaries and post-Amadori inhibition | |
JP2008514718A (ja) | 置換アゼチドノンおよびcb1アンタゴニストの組み合わせ | |
JP2000515526A (ja) | Mtp阻害剤と他のコレステロール低下薬を組合せて使用する、血清脂質レベルの降下方法 | |
JP2004517919A (ja) | 血管状態の処置のための心臓血管薬剤とステロール吸収インヒビターとの組み合わせ | |
US20050281868A1 (en) | Transdermal delivery system for statin combination therapy | |
US6235706B1 (en) | Combination therapy for reducing the risks associated with cardiovascular disease | |
CA2190107A1 (fr) | Compositions pour le traitement de maladies inflammatoires chroniques | |
AU723315B2 (en) | Combination therapy for reducing the risks associated with cardiovascular disease | |
JP2004517920A (ja) | 血管状態を治療するためのステロール吸収阻害剤と血液調整剤との組合せ | |
US6251852B1 (en) | Combination therapy for reducing the risks associated with cardiovascular disease | |
US20040220090A1 (en) | Advanced glycation end-product intermediaries and post-amadori inhibition | |
HRP960341A2 (en) | New methods of using n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters) | |
RO117297B1 (ro) | Metoda de tratament a alcoolismului cronic sau a starilor datorate abuzului de alcool | |
WO2014087231A2 (fr) | Composition pharmaceutique possédant une action neuro-protectrice, nootrope et anti-amnésique, et méthode de prévention et/ou de traitement d'états liés à une perturbation du flux sanguin dans le cerveau due à des maladies cérébrovasculaires et neurodégénératives | |
RU2703729C2 (ru) | Комбинация и набор с анксиолитическим действием | |
UA82480C2 (uk) | Застосування комбінації донепезилу та мемантину для лікування хвороби альцгеймера | |
JPH0311022A (ja) | 薬剤組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |